Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.

Anna Siemiątkowska Maciej Bryl Katarzyna Kosicka-Noworzyń Jakub TvrdoňIwona Gołda-GockaFranciszek K Główka

Published in: Cancer immunology, immunotherapy : CII (2023)

Serum sCD8 could be an early biomarker of durable disease control after anti-PD-L1 treatment. Higher sCD8 in patients with worse outcomes could suggest the inhibitory effect of sCD8 on cytotoxic T-cells activation.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
type diabetes
combination therapy
adipose tissue
insulin resistance
replacement therapy
tyrosine kinase
glycemic control